Vispa-Cel, an Allogeneic Anti-CD19 CAR-T cell Therapy with a PD-1 Knockout, In Patients with relapsed/refractory B cell Non-Hodgkin Lymphoma (r/r B-NHL): Updated Results from the Antler Phase 1 Clinical Trial

Mehdi Hamadani, Susan O'Brien, James Essell et al.|Transplantation and Cellular Therapy|2026

Cited by 0